Comparing Pulmonary Arterial Hypertension Care in Urban and Rural Settings: Treatment Patterns and Risk Trajectories, Pulmonary Circulation, November 11, 2025

Access to specialized care may differ between urban and rural patients, potentially influencing outcomes. A study conducted at the at the University of Utah Pulmonary Hypertension Center compared 263 pulmonary arterial hypertension patients from urban versus rural areas treated in the period 2020-2024. Similar at baseline: Important differences emerged: Conclusion: Despite similar care delivery and […]

Comparing Pulmonary Arterial Hypertension Care in Urban and Rural Settings: Treatment Patterns and Risk Trajectories, Pulmonary Circulation, November 11, 2025 Read Post »

New pulmonary arterial hypertension therapy CM5480 delivers encouraging results in rat model, Pulmonary Hypertension News, November 14, 2025

CM5480 is an experimental therapy being developed by Calcimedica, a US clinical-stage biopharmaceutical company. The findings of a new study titled “Combination of Orai1 inhibitor CM5480 with specific therapy mitigates pulmonary hypertension and its cardiac dysfunction” reveals that CM5480 was helpful in rat models when used on its own and provided additional benefits when combined

New pulmonary arterial hypertension therapy CM5480 delivers encouraging results in rat model, Pulmonary Hypertension News, November 14, 2025 Read Post »

Approach to Lung Transplantation in Pulmonary Arterial Hypertension: A Delphi Consensus on Behalf of the Transplant Task Force of the Pulmonary Vascular Research Institute (PVRI), April 2025

A modified Delphi consensus was conducted by the Pulmonary Vascular Research Institute (PVRI) Lung Transplantation Workstream, involving 29 international experts on pulmonary arterial hypertension (PAH) and lung transplantation. The process generated consensus ( mean scores >_2.5 on Likert scale ) across 141 out of 223 statements relating to when to refer pulmonary arterial hypertension patients

Approach to Lung Transplantation in Pulmonary Arterial Hypertension: A Delphi Consensus on Behalf of the Transplant Task Force of the Pulmonary Vascular Research Institute (PVRI), April 2025 Read Post »

Latest edition on the Council of Europe’s European Directorate for the Quality of Medicines and HealthCare (EDQM) Newsletter Transplant 2025 is now available

The Council of Europe’s EDQM (European Directorate for the Quality of Medicines and HealthCare) Newsletter Transplant provides regular updates on transplantation-related developments across Europe. It covers policy, regulation, quality standards, and best practices related to organ donation, allocation, and transplant safety, ensuring harmonisation across European Union member states. Additionally, the newsletter shares news on scientific

Latest edition on the Council of Europe’s European Directorate for the Quality of Medicines and HealthCare (EDQM) Newsletter Transplant 2025 is now available Read Post »

Integrating Sotatercept Into Pulmonary Arterial Hypertension (PAH) Care: Vallerie McLaughlin, MD, American Heart Association, November 9, 2025

Vallerie McLaughlin, MD, the Kim A. Eagle M.D. Endowed Professor of Cardiovascular Medicine and Professor of Internal Medicine at the University of Michigan Medical School, presented the results of a pooled analysis of the PULSAR, STELLAR, and ZENITH trials of sotatercept in pulmonary arterial hypertension at the 2025 American Heart Association Scientific Sessions, held in

Integrating Sotatercept Into Pulmonary Arterial Hypertension (PAH) Care: Vallerie McLaughlin, MD, American Heart Association, November 9, 2025 Read Post »

Cereno Scientific Submits Phase IIb Trial Protocol for CS1 in Pulmonary Arterial Hypertension (PAH) to the U.S. Food and Drug Administration (FDA), November 10, 2025

Cereno Scientific has submitted the clinical trial protocol for the planned global Phase IIb trial of its lead drug candidate CS1 to the U.S. Food and Drug Administration (FDA). CS1 is an oral histone deacetylase inhibitor (HDACi) intended as a disease-modifying therapy for pulmonary arterial hypertension (PAH), working through epigenetic modulation to target underlying mechanisms

Cereno Scientific Submits Phase IIb Trial Protocol for CS1 in Pulmonary Arterial Hypertension (PAH) to the U.S. Food and Drug Administration (FDA), November 10, 2025 Read Post »

First clinical site now open for large trial testing seralutinib for people with pulmonary hypertension associated with interstitial lung disease (PH-ILD), Pulmonary Hypertension News, November 7, 2025

The first clinical site is now active for a global Phase 3 study that will evaluate Gossamer Bio’s therapy candidate seralutinib for people with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The study, titled SERANATA, aims to enroll around 480 patients aged 18 to 80, randomised to receive either 90 mg or 120 mg

First clinical site now open for large trial testing seralutinib for people with pulmonary hypertension associated with interstitial lung disease (PH-ILD), Pulmonary Hypertension News, November 7, 2025 Read Post »

Preferences for pulmonary arterial hypertension (PAH) medications: insights from interviews with patients and doctors, Future Cardiology, November 4, 2025

A study titled “Single‑Tablet Combination Therapy of Macitentan/Tadalafil for Patients with Pulmonary Arterial Hypertension: Qualitative Interview Study” interviewed 26 pulmonary arterial hypertension patients and 18 doctors from the A DUE clinical trial, who tested the single-pill combination therapy (macitentan+tadalafil) versus taking multiple pills daily. Both patients and doctors agreed that taking one pill daily instead

Preferences for pulmonary arterial hypertension (PAH) medications: insights from interviews with patients and doctors, Future Cardiology, November 4, 2025 Read Post »

Study provides proof-of-concept that fully automated, algorithm-driven tacrolimus dosing can improve therapeutic drug monitoring in real-world clinical practice, Clinical Pharmacology and Therapeutics, October 11, 2025

Tacrolimus therapeutic drug monitoring is challenging due to high inter- and intra-patient variability. A prospective randomized controlled trial was conducted by researchers at the University Hospital in Leuven, Belgium, on 293 de novo kidney transplant recipients during the first 14 days post-transplant. A fully automated Model-informed precision dosing (MIPD) application (1) was integrated into the

Study provides proof-of-concept that fully automated, algorithm-driven tacrolimus dosing can improve therapeutic drug monitoring in real-world clinical practice, Clinical Pharmacology and Therapeutics, October 11, 2025 Read Post »

Explainer video on Right Heart Catheterisation (RHC) by the UK Pulmonary Hypertension Association’s PHA UK

Right heart catheterization (RHC) is an invasive diagnostic procedure used to measure pressures and blood flow in the right side of the heart and pulmonary arteries. It’s considered the gold standard for diagnosing and assessing pulmonary hypertension and other cardiovascular conditions. This video by the UK Pulmonary Hypertension Association PHA UK with Dr Charlie Elliott,

Explainer video on Right Heart Catheterisation (RHC) by the UK Pulmonary Hypertension Association’s PHA UK Read Post »

From Individual Responsibility to System Design: How Nations Are Building Health Literate Societies, a report by the World Health Organisation (WHO)

Kristine Sørensen founder of the Global Health Literacy Academy, President of the International Health Literacy Association, and Executive Chair of Health Literacy Europe, brings extensive expertise to the field of health literacy. She currently serves as a visiting lecturer at Bielefeld University in Germany, MCI School of Management in Innsbruck, Austria, and the Centre of

From Individual Responsibility to System Design: How Nations Are Building Health Literate Societies, a report by the World Health Organisation (WHO) Read Post »

GLP-1 receptor agonists linked to lower mortality, respiratory failure in pulmonary arterial hypertension, Healio News, October 23, 2025

A recent article in Healio news by Isabella Hornick summarises a study titled “Exploring the potential benefits of GLP-1 receptor agonists in pulmonary arterial hypertension: Insights from a large database study”, which was presented at the CHEST Annual Meeting October 19-22, 2025 in Chicago. GLP-1 receptor agonists (Glucagon-Like Peptide-1) are commonly used for diabetes and

GLP-1 receptor agonists linked to lower mortality, respiratory failure in pulmonary arterial hypertension, Healio News, October 23, 2025 Read Post »

Shaping the Future of Digital Health Technology (DHT) Assessment, Journal of Market Access & Health Policy, September 4, 2025

A 2025 study published in the Journal of Market Access & Health Policy explores the evolving role of digital health technologies in shaping patient experiences and healthcare delivery. The authors used a mixed-methods approach including a survey of 20 Digital Health Technology developers, and qualitative research with 29 industry representatives from startups to multinational companies

Shaping the Future of Digital Health Technology (DHT) Assessment, Journal of Market Access & Health Policy, September 4, 2025 Read Post »

Phenotyping of patients with mild pulmonary hypertension, Open Heart journal, October 10, 2025

A study on the importance of phenotyping patients with mild pulmonary hypertension was publslhed on the Open Heart journal on October 10, 2025. They found that most patients with mild precapillary pulmonary hypertension have underlying comorbidities rather than early-stage pulmonary arterial hypertension. Stroke volume index emerged as the key independent predictor of prognosis. Survival was

Phenotyping of patients with mild pulmonary hypertension, Open Heart journal, October 10, 2025 Read Post »

RARE 2025 Congress, October 8, 2025: Presenting research by the French Pulmonary Hypertension Association HTaPFrance on explaining the condition to children

A poster presented by the French Pulmonary Hypertension association HTaPFrance was displayed at the RARE 2025 Congress on October 8, 2025– see photo below with HTaPFrance President Maggy Surace. The poster presents data from a questionnaire that was sent to patients’ families and to the patients. It summarizes the section “Understanding the disease at the

RARE 2025 Congress, October 8, 2025: Presenting research by the French Pulmonary Hypertension Association HTaPFrance on explaining the condition to children Read Post »

Economic and Social Burden of Pulmonary Arterial Hypertension in Italy: A Cost-of-Illness Study, Drugs Real World Outcomes, October 17, 2025

A paper titled “Economic and Social Burden of Pulmonary Arterial Hypertension in Italy: A Cost-of-Illness Study” was recently pubclished in Drugs Real World Outcomes journal. The aim of the authors was to estimate the economic and social burden of pulmonary arterial hypertension (PAH) in Italy, including direct healthcare costs, direct non-healthcare costs, and indirect costs

Economic and Social Burden of Pulmonary Arterial Hypertension in Italy: A Cost-of-Illness Study, Drugs Real World Outcomes, October 17, 2025 Read Post »

Free publication of the month on “Menopause and Pulmonary Hypertension”, by the UK Pulmonary Hypertension Association PHA UK

Menopause affects all women in the pulmonary hypertension community at some stage of their life. A free publication by the Pulmonary Hypertension Association UK answers common questions, shares real experiences, and brings expert advice to support women who are going through the process. Order it here

Free publication of the month on “Menopause and Pulmonary Hypertension”, by the UK Pulmonary Hypertension Association PHA UK Read Post »

Mark the date for the National Pulmonary Hypertension Information Day in the Netherlands, November 22, 2025!

🫁 National Pulmonary Hypertension Information Day Date: 22 November 2025 | Time: 10:15 – 16:00Location: Congrescentrum De Schakel, Oranjelaan 10, 3862 CX Nijkerk 📍 Venue: Congrescentrum De Schakel, Nijkerk🎈 Theme: “Stronger Together”🎤 Chair: Arieke van Liere An inspiring day full of information, recognition, and connection—especially for people living with pulmonary hypertension, their loved ones, and

Mark the date for the National Pulmonary Hypertension Information Day in the Netherlands, November 22, 2025! Read Post »

Comparative efficacy and safety of prostacyclin therapies for pulmonary arterial hypertension: a systematic review and network meta-analysis, Frontiers in Medicine, October 2025

A network meta-analysis conducted by researchers at the Cleveland Clinic Abu Dhabi, published in the October 2025 edition of Frontiers in Medicine, compared the efficacy and safety of prostacyclin therapies for pulmonary arterial hypertension (PAH) by synthesizing data from 32 studies, comprising 24 randomised controlled trials, three open-label trials,and five cohort studies, with a cumulative

Comparative efficacy and safety of prostacyclin therapies for pulmonary arterial hypertension: a systematic review and network meta-analysis, Frontiers in Medicine, October 2025 Read Post »

How Medicine Missed Viagra’s True Potential, MedPage Today, October 15, 2025

A recent article by Bharat Desai, an American physician specializing in internal medicine and pulmonary disease, argues that sildenafil could have revolutionized cardiovascular prevention, but was relegated to being an erectile dysfunction drug due to the at-the-time medical environment’s obsession with cholesterol. The Forgotten Origins Sildenafil was originally developed in the early 1990s as a

How Medicine Missed Viagra’s True Potential, MedPage Today, October 15, 2025 Read Post »

TRANSLATE »
Scroll to Top